Cogent Biosciences

Andrew Robbins serves as CEO and President. The board of directors includes a founding partner from Fairmount Funds Management. The chief scientific officer oversees discovery and pipeline decisions (firm website).

Cogent's candidates are designed internally by its Boulder-based discovery team, focusing on validated genetic targets. The company does not license or in-license external assets; it develops small-molecule drugs from scratch (firm website).

Neither. Cogent is a publicly traded biotechnology corporation (Nasdaq). Its capital structure comes from public equity markets, not a single family or private fund.

Cogent operates as a discovery-to-development biotech. It funds early-stage research and preclinical work, aiming to advance candidates through clinical trials on its own. No disclosed partnership or co-development model.

Cogent focuses solely on small-molecule precision therapies for genetically defined diseases. It does not invest in medical devices, diagnostics, gene therapies, vaccines, or large-molecule biologics.

Fairmount Funds Management LLC has a board representative at Cogent: a founding partner and the director of research serve on Cogent's board of directors. Fairmount is an investment firm, not a parent company.

Cogent runs a patient advocacy program and an expanded access program (EAP) for investigational therapies, but no separate philanthropic foundation is disclosed on its website.